MHC I–restricted epitopes of chicken ovalbumin (OVA) were originally identified using CD8+ T cells as probes. Here, using bioinformatics tools, we identify 4 additional epitopes in OVA in addition to a cryptic epitope. Each additional epitope is presented in vivo, as deduced from the lack of CD8+ T cell response to it in OVA-transgenic mice. In addition, CD8 responses to the previously known epitopes and those identified in this study are examined in C57BL/6J mice exposed to the OVA-expressing tumor E.G7 in several ways. No responses to any epitope, including SIINFEKL, are detected in mice with growing E.G7 or mice immunized with the tumor. Only in E.G7-bearing mice treated with an anti–CTLA-4 antibody, which depletes tumor-infiltrating regulatory T cells, are CD8 responses to SIINFEKL and the epitope EKYNLTSVL identified in this study detected. Finally, all epitopes fail to treat mice with preexisting tumors. These observations force an important reconsideration of the common assumptions about the therapeutic value of neoepitopes detected by CD8 responses in tumor-bearing hosts.
Sukrut Hemant Karandikar, John Sidney, Alessandro Sette, Mark Joseph Selby, Alan Jerry Korman, Pramod Kumar Srivastava
Title and authors | Publication | Year |
---|---|---|
Antigenic peptide delivery to antigen-presenting cells using a CD40-coiled coil affinity-based platform
Nyesiga B, Hägerbrand K, Varas L, Gjörloff Wingren A, Ohlin M, Ellmark P, von Schantz L |
Drug Delivery | 2025 |
A frameshift-generated cancer neoepitope that controls tumor burden in prophylaxis as well as therapy
George MM, Brennick CA, Hagymasi AT, Shcheglova TV, Al Seesi S, Rosales TJ, Baker BM, Mandoiu II, Srivastava PK |
The Journal of Immunology Author Choice | 2025 |
Cancer neoepitopes: Awaiting “the simplicity on the other side of complexity”
Pramod K. Srivastava |
Journal of Clinical Investigation | 2024 |
Tutorial: design, production and testing of oncolytic viruses for cancer immunotherapy.
Gujar S, Pol JG, Kumar V, Lizarralde-Guerrero M, Konda P, Kroemer G, Bell JC |
Nature Protocols | 2024 |
Impact of hydrophobic modification on biocompatibility of Alaska pollock gelatin microparticles.
Yee YC, Mori T, Ito S, Taguchi T, Katayama Y |
2024 | |
CD8+ T Cell-Dependent Antitumor Activity In Vivo of a Mass Spectrometry-Identified Neoepitope despite Undetectable CD8+ Immunogenicity In Vitro.
Gillig MA, Brennick CA, George MM, Balsbaugh JL, Shcheglova TV, Mandoiu II, Rosales T, Baker BM, Srivastava PK, Karandikar SH |
Journal of immunology (Baltimore, Md. : 1950) | 2023 |
Utility of a Recombinant HSV-1 Vaccine Vector for Personalized Cancer Vaccines
I Uche, B Stanfield, J Rudd, K Kousoulas, P Rider |
Frontiers in Molecular Biosciences | 2022 |
Recent advances in surface modification of micro- and nano-scale biomaterials with biological membranes and biomolecules.
Abesekara MS, Chau Y |
Frontiers in Bioengineering and Biotechnology | 2022 |
An unbiased approach to defining bona fide cancer neoepitopes that elicit immune-mediated cancer rejection
Cory A. Brennick, Mariam M. George, Marmar R. Moussa, Adam T. Hagymasi, Sahar Al Seesi, Tatiana V. Shcheglova, Ryan P. Englander, Grant L.J. Keller, Jeremy L. Balsbaugh, Brian M. Baker, Andrea Schietinger, Ion I. Mandoiu, Pramod K. Srivastava |
Journal of Clinical Investigation | 2021 |
Systemic inhibition of PTPN22 augments anticancer immunity
Won Jin Ho, Sarah Croessmann, Jianping Lin, Zaw H. Phyo, Soren Charmsaz, Ludmila Danilova, Aditya A Mohan, Nicole Gross, Fangluo Chen, Jiajun Dong, Devesh Aggarwal, Yunpeng Bai, Janey Wang, Jing He, James m Leatherman, Mark Yarchoan, Todd D. Armstrong, Neeha Zaidi, Elana J Fertig, Joshua C Denny, Ben Park, Zhong-Yin Zhang, Elizabeth Jaffee |
Journal of Clinical Investigation | 2021 |
Low neoantigen expression and poor T-cell priming underlie early immune escape in colorectal cancer
PM Westcott, NJ Sacks, JM Schenkel, ZA Ely, O Smith, H Hauck, AM Jaeger, D Zhang, CM Backlund, MC Beytagh, JJ Patten, R Elbashir, G Eng, DJ Irvine, OH Yilmaz, T Jacks |
2021 | |
Technical choices significantly alter the adaptive immune response against immunocompetent murine gliomas in a model-dependent manner
B Noffsinger, A Witter, N Sheybani, A Xiao, L Manigat, Q Zhong, S Taori, T Harris, T Bullock, R Price, B Purow |
Journal of Neuro-Oncology | 2021 |
Nanocarrier-Based Drug Delivery for Melanoma Therapeutics
M Song, C Liu, S Chen, W Zhang |
International journal of molecular sciences | 2021 |
A Combined Adjuvant TF–Al Consisting of TFPR1 and Aluminum Hydroxide Augments Strong Humoral and Cellular Immune Responses in Both C57BL/6 and BALB/c Mice
Q Li, Z Liu, Y Liu, C Liang, J Shu, X Jin, C Li, Z Kou |
Human vaccines | 2021 |
Oncolytic Maraba virus armed with tumor antigen boosts vaccine priming and reveals diverse therapeutic response patterns when combined with checkpoint blockade in ovarian cancer
AJ McGray, RY Huang, S Battaglia, C Eppolito, A Miliotto, KB Stephenson, AA Lugade, G Webster, BD Lichty, M Seshadri, D Kozbor, K Odunsi |
Journal for ImmunoTherapy of Cancer | 2019 |